BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, originally derived from a protective protein found in human gastric juice. Unlike hormones or steroids, BPC-157 is a signaling peptide — it works by modulating the body's existing repair machinery rather than replacing or suppressing it. The compound was first isolated by Croatian researcher Dr. Predrag Sikiric and his team at the University of Zagreb, where it has been studied extensively in animal models since the 1990s. Research has demonstrated effects on tendon and ligament healing, gastrointestinal repair, inflammation, and even neurological recovery following injury. BPC-157 is currently classified as a research chemical and is not approved for human use by the FDA or equivalent regulatory bodies. All available evidence in humans is anecdotal; the controlled studies underpinning its reputation have been conducted in rats and other rodents. Despite this, it has become one of the most widely discussed healing peptides among athletes, biohackers, and longevity researchers.

The majority of BPC-157's documented benefits come from preclinical animal studies, where the compound has demonstrated a remarkably broad range of tissue-protective effects. Tendon and ligament healing is where BPC-157 has the strongest body of evidence. Multiple rodent studies have shown accelerated recovery from Achilles tendon transection, rotator cuff tears, and ligament injuries. The mechanism involves upregulation of growth factor receptors (specifically EGF and VEGF) and promotion of angiogenesis — the formation of new blood vessels that supply healing tissue with oxygen and nutrients. Gastrointestinal repair is another well-studied area. BPC-157 has shown protective effects against ulcers induced by NSAIDs, alcohol, and stress, and has accelerated healing of fistulas and inflammatory bowel lesions in animal models. Systemic anti-inflammatory properties have also been observed, with BPC-157 modulating nitric oxide pathways and suppressing inflammatory cytokines in ways that reduce collateral tissue damage during injury recovery.

BPC-157 has an unusually favorable safety profile in animal studies, with no observed toxicity even at high doses across chronic administration periods. However, the absence of controlled human trials means the true side effect profile in people is not well characterized. The most commonly reported adverse effects in human anecdotal use are mild and injection-site specific: localized redness, swelling, or discomfort at the SubQ or IM injection site. These typically resolve within 24–48 hours. One theoretical concern is the pro-angiogenic activity of BPC-157 — the same mechanism that accelerates tissue repair also stimulates new blood vessel formation. In the context of occult cancers or pre-existing tumors, this could theoretically support tumor vascularization. No evidence of this has been demonstrated in BPC-157-specific studies, but it warrants caution in individuals with a cancer history.

Standard systemic dose: 250–500 mcg per day, administered as a single SubQ injection or split into two injections of 125–250 mcg. For systemic effects, SubQ injection in the abdominal region is preferred. Injury-specific local dosing: For targeted tendon, ligament, or joint recovery, injecting closer to the site of injury is commonly practiced. The same 250–500 mcg daily range applies. Cycle length: Most practitioners run BPC-157 in 4–8 week cycles, followed by a break of equal or longer duration. Oral dosing: For gastrointestinal applications, oral dosing (500 mcg to 2 mg/day) may be appropriate and avoids injections. Reconstitution: BPC-157 is typically sold as a lyophilized powder reconstituted with bacteriostatic water before injection. Standard reconstitution is 1–2 mL of bac water per vial, using an insulin syringe (28–31 gauge).

United States: Not FDA approved for human use and not a scheduled controlled substance. Legal to purchase for research purposes, sold as "research chemical" and labeled "not for human consumption." European Union: Varies by member state. Most EU countries treat it as a regulatory gray area — not explicitly controlled but not approved for human use. Australia: On the TGA's list of prohibited imports without a valid prescription. Possession without prescription can carry legal consequences. WADA / Sports: Not currently on the World Anti-Doping Agency's prohibited list, though athletes at the elite level should consult their sport's governing body.

BPC-157 + TB-500: The most popular healing stack. TB-500 works through actin upregulation and systemic cell migration, complementing BPC-157's local angiogenic activity. A common protocol pairs BPC-157 at 250–500 mcg/day with TB-500 at 2–2.5 mg twice per week. BPC-157 + GHK-Cu: Adds collagen synthesis stimulation and antioxidant activity for connective tissue recovery. BPC-157 + Ipamorelin/CJC-1295: Adding a GH secretagogue complements BPC-157's targeted tissue effects with systemic growth hormone elevation.

BPC-157 — Common Questions